American Journal of Cardiovascular Drugs

, Volume 2, Issue 5, pp 323–334

Prevention of Restenosis with Antioxidants

Mechanisms and Implications
  • Jean-Claude Tardif
  • Jean Grégoire
  • Philippe L. L’Allier
Review Article


The aim of this review is to give an overview of the field of restenosis prevention with antioxidants, put in the perspective of their potential use for the prevention of atherosclerosis progression. Compelling evidence points to oxidative stress as an important trigger in the complex chain of events leading to atherosclerosis. There is also evidence that oxidative stress occurs early after angioplasty. Reactive oxygen species (ROS) can induce endothelial dysfunction and macrophage activation, resulting in the release of cytokines and growth factors that stimulate matrix remodeling and smooth muscle cell proliferation. The accumulation of new extracellular matrix and smooth muscle cells will result in the neointimal formation responsible for lumen narrowing after stent deployment and which contributes to that after balloon angioplasty. In addition, oxidation processes are involved in the cross-linking of collagen fibers, and this coupled with smooth muscle cell contraction and endothelial dysfunction may result in long-term vascular constriction or lack of adaptive vascular remodeling after balloon angioplasty.

The powerful antioxidant probucol has been shown to prevent coronary restenosis after balloon angioplasty in the Multivitamins and Probucol (MVP) trial and other clinical studies. However, prolongation of the QT interval with probucol remains a long-term safety concern.

AGI-1067, a metabolically stable analog of probucol, is a vascular protectant with strong antioxidant properties as potent to those of probucol. There has been no evidence of prolongation of the QT interval with AGI-1067 in initial clinical studies. The anti-restenosis properties of AGI-1067 are being assessed in the Canadian Antioxidant Restenosis Trial (CART)-1. Considering that oxidative stress and inflammation may persist for a prolonged period after stent placement, treatment with AGI-1067 for the entire period of risk after percutaneous coronary intervention (PCI) [instead of only 4 weeks in CART-1] may result in enhanced protection against luminal renarrowing. This hypothesis will be tested in the randomized, multicenter CART-2 trial. AGI-1067 has been effective at preventing atherosclerosis in all tested animal models, including the low density lipoprotein receptor-deficient and apo-E knockout mice. This has potentially important implications, as PCI and local approaches to prevent restenosis such as coated Stents are not expected to prevent atherosclerosis progression, myocardial infarction and cardiovascular death. As the ultimate goal of therapy for patients with coronary artery disease must remain prevention of disease progression and atherosclerosis-related events, CART-2 will test the value of AGI-1067 for the reduction of both post-PCI restenosis and atherosclerosis progression.


  1. 1.
    Tardif JC, Grégoire J, Bourassa MG. Antioxidants and restenosis: human studies. In: Tardif JC, Bourassa MG, editors. Antioxidants and cardiovascular disease. Dordrecht, The Netherlands, Kluwer Academic Publishers, 2000: 175–94CrossRefGoogle Scholar
  2. 2.
    Shi Y, Niculescu R, Wang D, et al. Increased NADPH oxidase and reactive oxygen species in coronary arteries after balloon injury. Arterioscler Thromb Vasc Biol 2001; 21:739–45PubMedCrossRefGoogle Scholar
  3. 3.
    Mason RP, Walter MF, Mason PE. Effect of oxidative stress on membrane structure: Small angle x-ray diffraction analysis. Free Radic Biol Med 1997; 23: 419–25Google Scholar
  4. 4.
    Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915–24PubMedCrossRefGoogle Scholar
  5. 5.
    Brawn K, Fridovich I. DNA strand scission by enzymically generated oxygen radicals. Arch Biochem Biophys 1981; 206: 414–9PubMedCrossRefGoogle Scholar
  6. 6.
    Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85: 753–66PubMedCrossRefGoogle Scholar
  7. 7.
    Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115–26PubMedCrossRefGoogle Scholar
  8. 8.
    Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 1990; 87: 5134–8PubMedCrossRefGoogle Scholar
  9. 9.
    Marui N, Offermann MK, Swerlick R, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92: 1866–74PubMedCrossRefGoogle Scholar
  10. 10.
    Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990; 344: 254–7PubMedCrossRefGoogle Scholar
  11. 11.
    Bourcier T, Sukhova G, Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997; 272: 15817–24PubMedCrossRefGoogle Scholar
  12. 12.
    Thomas CE, Jackson RL, Ohlweiler DF, et al. Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 α release from human blood mononuclear cells. J Lipid Res 1994; 35: 417–27PubMedGoogle Scholar
  13. 13.
    Rajagopalan S, Meng XP, Ramasamy S, et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 1996; 98: 2572–9PubMedCrossRefGoogle Scholar
  14. 14.
    Ikeda H, Koga Y, Oda T, et al. Free oxygen radicals contribute to platelet aggregation and cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. J Am Coll Cardiol 1994; 24: 1749–56PubMedCrossRefGoogle Scholar
  15. 15.
    Roberts MJD, Young IS, Trouton TG, et al. Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet 1990; 336: 143–5PubMedCrossRefGoogle Scholar
  16. 16.
    Iuliano L, Pratico D, Greco C, et al. Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 2001; 37: 76–80PubMedCrossRefGoogle Scholar
  17. 17.
    Kugiyama K, Kerns SA, Morissett JD, et al. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344: 160–2PubMedCrossRefGoogle Scholar
  18. 18.
    Bendeck MP, Zempro N, Clowes AW, et al. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994; 75: 539–45PubMedCrossRefGoogle Scholar
  19. 19.
    Strauss BH, Chisholm RJ, Keeley FW, et al. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res 1994; 75: 650–8PubMedCrossRefGoogle Scholar
  20. 20.
    Hoffman R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis. Circulation 1996; 94: 1247–54CrossRefGoogle Scholar
  21. 21.
    Reiser K, McCormick RJ, Rucker RB. Enzymatic and nonenzymatic cross-linking of collagen and elastin. FASEB J 1992; 6: 2439–49PubMedGoogle Scholar
  22. 22.
    Lafont A, Durand E, Samuel JL, et al. Endothelial dysfunction and collagen accumulation. Two independent factors for restenosis and constructive remodeling after experimental angioplasty. Circulation 1999; 100: 1109–15PubMedCrossRefGoogle Scholar
  23. 23.
    Langille BL, O’Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science 1986; 231: 405–7PubMedCrossRefGoogle Scholar
  24. 24.
    Ferns GAA, Forster L, Stewart-Lee A, et al. Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc Natl Acad Sci U S A 1992; 89: 11312–6PubMedCrossRefGoogle Scholar
  25. 25.
    Schneider JE, Berk BC, Gravanis MB, et al. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury: a possible role for antioxidants in restenosis. Circulation 1993; 88: 628–37PubMedCrossRefGoogle Scholar
  26. 26.
    Freyschuss A, Stiko-Rahm A, Swedenborg J, et al. Antioxidant treatment inhibits the development of intimai thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J Clin Invest 1993; 91: 1282–8PubMedCrossRefGoogle Scholar
  27. 27.
    Nunes GL, Sgoutas DS, Redden RA, et al. Combination of vitamins C and E alters the response to coronary balloon injury in the pig. Arterioscler Thromb Vasc Biol 1995; 15: 156–65PubMedCrossRefGoogle Scholar
  28. 28.
    Lafont A, Vinchon F, Addad F, et al. Antioxidants and restenosis: animal studies. In: Tardif JC, Bourassa MG, editors. Antioxidants and cardiovascular disease. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2000: 161–74CrossRefGoogle Scholar
  29. 29.
    Lee YJ, Yamaguchi H, Daida H, et al. Pharmacological interventions to modify restenosis [abstract]. Circulation 1991; 84:II–299Google Scholar
  30. 30.
    Setsuda M, Inden M, Hiraoka N, et al. Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Clin Ther 1993; 15:374–81PubMedGoogle Scholar
  31. 31.
    Watanabe K, Sekyia M, Ikeda S, et al. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996; 132: 23–9PubMedCrossRefGoogle Scholar
  32. 32.
    Lee YJ, Daida H, Yokoi H, et al. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J 1996; 37: 327–32PubMedCrossRefGoogle Scholar
  33. 33.
    Tardif JC, Côté G, Lespérance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337: 365–72PubMedCrossRefGoogle Scholar
  34. 34.
    Rodés J, Tardif JC, Lespérance J, et al. Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation 1998; 97: 429–36PubMedCrossRefGoogle Scholar
  35. 35.
    Côté G, Tardif JC, Lespérance J, et al. Effects of probucol on vascular remodeling after coronary angioplasty. Circulation 1999; 99: 30–5PubMedCrossRefGoogle Scholar
  36. 36.
    Tardif JC, Côté G, Lespérance J, et al. Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial. Can J Cardiol 2001; 17: 49–55PubMedGoogle Scholar
  37. 37.
    O’Keefe Jr JH, Stone GW, McCallister Jr BD, et al. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1996; 77: 649–52PubMedCrossRefGoogle Scholar
  38. 38.
    Reaven PD, Parthasarathy S, Beltz WF, et al. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler Thromb 1992; 12: 318–24PubMedCrossRefGoogle Scholar
  39. 39.
    Tardif JC, Grégoire J. Antioxidants and prevention of restenosis after directional coronary atherectomy. Circulation 2000; 103: e51–e52CrossRefGoogle Scholar
  40. 40.
    Edelman ER. Vessel size, antioxidants, and restenosis. Never too small, not too little, but often too late. Circulation 1998; 97: 416–20PubMedCrossRefGoogle Scholar
  41. 41.
    Bowry VW, Ingold KU, Stocker R. Vitamin E in human low-density lipoprotein: when and how this antioxidant becomes a pro-oxidant. Biochem J 1992; 288: 341–4PubMedGoogle Scholar
  42. 42.
    Gaziano JM, Hatta A, Flynn M, et al. Supplementation with α-carotene in vivo and in vitro does not inhibit low density lipoprotein oxidation. Atherosclerosis 1995; 112: 187–95PubMedCrossRefGoogle Scholar
  43. 43.
    Keaney Jr JF, Gaziano JM, Xu A, et al. Low-dose β-tocopherol improves and high-dose β-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994; 93: 844–51PubMedCrossRefGoogle Scholar
  44. 44.
    Yokoi H, Daida H, Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997; 30: 855–62PubMedCrossRefGoogle Scholar
  45. 45.
    Yokoi H, Daida H, Yamaguchi H, et al., for the PART Group. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty in small coronary arteries: a subgroup analysis of the Probucol Angioplasty Restenosis Trial (PART) [abstract]. J Am Coll Cardiol 1997; 29: 418AGoogle Scholar
  46. 46.
    Buckley MMT, Goa KL, Price AH, et al. Probucol: a reappraisal of its pharmacological properties and therapeutic use in hypercholesterolemia. Drugs 1989; 37: 761–800PubMedCrossRefGoogle Scholar
  47. 47.
    Parthasarathy S, Young SG, Witzum JL, et al. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986; 77: 641–4PubMedCrossRefGoogle Scholar
  48. 48.
    Chisolm GM III, Morel DW. Lipoprotein oxidation and cytotoxicity: effect of probucol on streptozotocin-treated rats. Am J Cardiol 1988; 62: 20B–6BCrossRefGoogle Scholar
  49. 49.
    Sasahara M, Raines EW, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the non-human primate by probucol. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 1994; 94: 155–64Google Scholar
  50. 50.
    Steinberg D, Parthasarathy S, Carew TE. In vivo inhibition of foam cell development by probucol in Watanabe rabbits. Am J Cardiol 1988; 62: 6B–12BPubMedCrossRefGoogle Scholar
  51. 51.
    Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A 1987; 84: 7725–9PubMedCrossRefGoogle Scholar
  52. 52.
    Ku G, Doherty NS, Wolos JA, et al. Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis. Am J Cardiol 1988; 62: 77B–81BPubMedCrossRefGoogle Scholar
  53. 53.
    Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488–93PubMedCrossRefGoogle Scholar
  54. 54.
    Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996; 93: 1647–50PubMedCrossRefGoogle Scholar
  55. 55.
    Reinoehl J, Frankovich D, Machado C, et al. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J 1996; 131: 1184–91PubMedCrossRefGoogle Scholar
  56. 56.
    Gohn DC, Simmons TW. Polymorphic ventricular tachycardia (torsades de pointe) associated with the use of probucol. N Engl J Med 1992; 326: 1435–6PubMedGoogle Scholar
  57. 57.
    Kajinami K, Takeoshi N, Mabuchi H. Propanolol for probucol-induced QT prolongation with polymorphic ventricular tachycardia. Lancet 1993; 341: 124–5PubMedCrossRefGoogle Scholar
  58. 58.
    Matsuhashi H, Onodera S, Kawamura Y, et al. Probucol-induced QT prolongation and torsades de pointes. Jpn J Med 1989; 28: 612–5PubMedCrossRefGoogle Scholar
  59. 59.
    Naruszewicz M, Carew TE, Pittman RC, et al. A novel mechanism by which probucol lowers LDL levels demonstrated in the LDL-receptor-deficient rabbit. J Lipid Res 1984; 25: 1206–13PubMedGoogle Scholar
  60. 60.
    Schwartz CJ. The probucol experience: a review of the past and a look at the future. Am J Cardiol 1988; 61: 1B–5BCrossRefGoogle Scholar
  61. 61.
    Rinninger F, Wang N, Ramakrishan R, et al. Probucol enhances selective uptake of MDL-associated cholesteryl esters in vitro by a scavenger receptor B-I dependent mechanism. Arteriscler Thromb Vasc Biol 1999; 19: 1325–32CrossRefGoogle Scholar
  62. 62.
    Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994; 74: 875–83PubMedCrossRefGoogle Scholar
  63. 63.
    Johansson J, Olsson AG, Bergstrand L, et al. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) report. Arterioscler Thromb Vasc Biol 1995; 15: 1049–56PubMedCrossRefGoogle Scholar
  64. 64.
    Sawayama Y, Shinizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. J Am Coll Cardiol 2002; 39: 610–6PubMedCrossRefGoogle Scholar
  65. 65.
    Steinberg D. Studies on the mechanism of action of probucol. Am J Cardiol 1986; 57: 16H–21HPubMedCrossRefGoogle Scholar
  66. 66.
    Kuzuya M, Naito M, Funaki C, et al. Probucol prevents oxidative injury to endothelial cells. J Lipid Res 1991; 32: 197–204PubMedGoogle Scholar
  67. 67.
    Yamamoto A, Hara H, Takaichi S, et al. Effect of probucol on macrophages, leading to regression of Xanthomas and atheromatous vascular lesions. Am J Cardiol 1988; 62: 31B–6BPubMedCrossRefGoogle Scholar
  68. 68.
    Chang MY, Sasahara M, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the non-human primate by probucol. Cellular composition and proliferation. Arterioscler Thromb Vasc Biol 1995; 15: 1631–40PubMedCrossRefGoogle Scholar
  69. 69.
    Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994; 331: 1331–7PubMedCrossRefGoogle Scholar
  70. 70.
    Galis ZA, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75: 181–9PubMedCrossRefGoogle Scholar
  71. 71.
    Tardif JC. The future of intravascular ultrasound in the detection and management of coronary artery disease. Can J Cardiol 2000; 16 Suppl. D: 12D–5DPubMedGoogle Scholar
  72. 72.
    Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996; 94: 35–43PubMedCrossRefGoogle Scholar
  73. 73.
    DiMario C, Gil R, Camenzind E, et al. Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy. Am J Cardiol 1995; 75: 772–7CrossRefGoogle Scholar
  74. 74.
    Kimura T, Kaburagi S, Tamura T, et al. Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Circulation 1997; 96: 475–83PubMedCrossRefGoogle Scholar
  75. 75.
    Christen WG, Hennekens CH. Antioxidant vitamins and cardiovascular disease: Evidence from observational epidemiologic studies and randomized trials. In: Tardif JC, Bourassa MG, editors. Antioxidants and cardiovascular disease. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2000: 135–44CrossRefGoogle Scholar
  76. 76.
    The α-Tocopherol, α-Carotene Cancer Prevention Study Group. The effect of vitamin E and α carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029–35CrossRefGoogle Scholar
  77. 77.
    Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of α carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150–5PubMedCrossRefGoogle Scholar
  78. 78.
    Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781–6PubMedCrossRefGoogle Scholar
  79. 79.
    Gruppo Italiano per lo Studio della Sopravivenza nell’Infarcto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447–55CrossRefGoogle Scholar
  80. 80.
    The HOPE Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 154–60CrossRefGoogle Scholar
  81. 81.
    Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20. Lancet 2002; 360 (9326): 23-33Google Scholar
  82. 82.
    Cooney RV, Franke AA, Harwood PJ, et al. γ-Tocopherol detoxification of nitrogen dioxide: Superiority to β-tocopherol. Proc Natl Acad Sci U S A 1993; 90:1771–5PubMedCrossRefGoogle Scholar
  83. 83.
    Christen S, Woodall AA, Shigenaga MK, et al. γ-Tocopherol traps mutagenic electrophiles such as NOx and complements β-tocopherol: physiological implications. Proc Natl Acad Sci U S A 1997; 94: 3217–22PubMedCrossRefGoogle Scholar
  84. 84.
    Handelman GJ, Machlin LJ, Fitch K, et al. Oral β-tocopherol supplements decrease plasma γ-tocopherol levels in humans. J Nutr 1985; 115: 807–13PubMedGoogle Scholar
  85. 85.
    Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583–92PubMedCrossRefGoogle Scholar
  86. 86.
    Serruys PW, Foley DP, Höfling B, et al. Carvedilol for the prevention of restenosis after directional coronary atherectomy: final results of the European Carvedilol Atherectomy Restenosis (EUROCARE) trial. Circulation 2000; 101: 1512–8PubMedCrossRefGoogle Scholar
  87. 87.
    Feuerstein GZ, Ruffolo RR. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995; 16 Suppl. F: 38–42PubMedGoogle Scholar
  88. 88.
    Yue TL, McKenna PJ, Lysko PG, et al. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 1992; 97: 209–16PubMedCrossRefGoogle Scholar
  89. 89.
    Mason RP, Walter MF, Trambore MW, et al. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999; 31:275–81PubMedCrossRefGoogle Scholar
  90. 90.
    Jorgensen B, Simonsen S, Endresen K, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES). J Am Coll Cardiol 2000; 35: 592–9PubMedCrossRefGoogle Scholar
  91. 91.
    Chen YL, Lin KF, Shiao MS, et al. Magnolol, a potent antioxidant from Magnolia officinalis, attenuates intimai thickening and MCP-1 expression after balloon injury of the aorta in cholesterol-fed rabbits. Basic Res Cardiol 2001; 96: 353–63PubMedCrossRefGoogle Scholar
  92. 92.
    Meng CQ, Somers PK, Rachita CL, et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. In press. Bioorg Med Chem Lett 2002Google Scholar
  93. 93.
    Somers PK, Medford RM, Saxena U. Dithiocarbamates: effects on lipid hydroperoxide and vascular inflammatory gene expression. Free Radic Biol Med 2000; 28 (10): 1532–7PubMedCrossRefGoogle Scholar
  94. 94.
    Nunes GL, Robinson K, Kalynych A, et al. Vitamins C and E inhibit O2- production in the pig coronary artery. Circulation 1997; 96: 3593–601PubMedCrossRefGoogle Scholar
  95. 95.
    L’Allier PL, Grégoire J, Joyal M, et al. Persistently elevated levels of soluble CD-40 ligand one month after percutaneous coronary angioplasty correlate with 6-month restenosis [abstract]. J Am Coll Cardiol 2002; 39: 32ACrossRefGoogle Scholar
  96. 96.
    Sundell CL, Dougherty A, Salvey AL, et al. Suppression of VCAM-1 and MCP-1 attenuates atherosclerosis in LDL-receptor-knockout and Apo-E knockout mouse models. [abstract]. Circulation 1999; 100: 42CrossRefGoogle Scholar
  97. 97.
    Tardif JC, Bertrand OF, Mongrain R, et al. Reliability of mechanical and phasedarray designs for serial intravascular ultrasound examinations. Int J Card Imaging 2000; 16: 365–75PubMedCrossRefGoogle Scholar
  98. 98.
    Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated Stents in human coronary arteries. A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103: 192–5PubMedCrossRefGoogle Scholar
  99. 99.
    Morice MC, Serruys PW, Sousa E, et al. A randomized comparison of a sirolimuseluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346 (23): 1773–80PubMedCrossRefGoogle Scholar
  100. 100.
    Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001; 104: 473–9PubMedCrossRefGoogle Scholar
  101. 101.
    Serruys PW. Oral presentation during the American College of Cardiology (ACC) Interventional Symposium, 51st Annual Scientific Sessions for the ACC. Atlanta, Georgia, 2002, Mar 17-20Google Scholar
  102. 102.
    Costa MA, Sabat M, van der Giessen WJ, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999; 100: 789–92PubMedCrossRefGoogle Scholar
  103. 103.
    Ishizaka N, Kurokawa K, Taguchi J, et al. Inhibitory effect of a single local probucol administration on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis 1995; 118: 53–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Jean-Claude Tardif
    • 1
  • Jean Grégoire
    • 1
  • Philippe L. L’Allier
    • 1
  1. 1.Department of MedicineMontreal Heart InstituteMontrealCanada

Personalised recommendations